Document is current
Any future updates will be listed below
-
Authors
Miller, Natalie J.
Church, Candice D.
Fling, Steven P.
Kulikauskas, Rima
Ramchurren, Nirasha
Shinohara, Michi M.
Kluger, Harriet M.
Bhatia, Shailender
Lundgren, Lisa
Cheever, Martin A.
Topalian, Suzanne L.
Nghiem, Paul https://orcid.org/0000-0003-2784-963X
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA015704, K24 CA139052, R01 CA162522)
Prostate Cancer Foundation (15CHAS04)
- License Information
-
More Information
Article History
Received: 30 July 2018
Accepted: 12 November 2018
First Online: 27 November 2018
Ethics approval and consent to participate
: The protocol was approved by the institutional review board at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All the patients provided written informed consent before study entry.
: Patients provided informed consent for publication of de-identified data. The consent is held by the Cancer Immunotherapy Trials Network and is available for review.
: PN serves as a paid consultant for EMD Serono. Bristol Myers Squibb has provided research support to PN’s institution. SLT has research grants from Bristol-Myers Squibb, and receives consulting fees and stock from Five Prime Therapeutics; her spouse receives consulting fees from Amgen, Compugen, MedImmune, Merck, Pfizer, and Potenza Therapeutics, and receives stock options from Compugen, Jounce Therapeutics, and Potenza.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
